Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4872524 | 1.00 | ATM (0.56) | ATML3MBTL1POLBCYP3A4CYP2D6 | |
| SCHEMBL18766866 | 0.97 | POLB (0.56) | ATML3MBTL1POLBCYP3A4CYP2D6 | |
| SCHEMBL18766868 | 0.97 | POLB (0.56) | ATML3MBTL1POLBCYP3A4CYP2D6 | |
| SCHEMBL4860714 | 0.89 | ALDH1A1 (0.54) | POLBMAPTLMNATP53THRB | |
| SCHEMBL4860708 | 0.89 | ALDH1A1 (0.54) | POLBMAPTLMNATP53THRB | |
| SCHEMBL18766740 | 0.85 | POLB (0.55) | POLBTP53 | |
| SCHEMBL18766742 | 0.85 | POLB (0.55) | POLBTP53 | |
| SCHEMBL4870223 | 0.84 | TP53 (0.57) | POLBCYP2D6MAPTLMNATP53 | |
| SCHEMBL4868334 | 0.79 | POLB (0.59) | L3MBTL1POLBMAPTLMNATP53 | |
| SCHEMBL4868227 | 0.78 | POLB (0.60) | POLBMAPTLMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368444-B2 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20050101600-A1 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1475368-A1 | N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101600-A1 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | CNR1, CNR2, NPSR1 | ATM 2852/4885L3MBTL1 4626/4885POLB 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.